Molecular Pathology in Drug Discovery and Development

The pharmaceutical industry is looking for new ways to better identify populations that will react positively to new drugs, and molecular pathology can fill that need.

Informationen zum Autor J. Suso Platero is Director of Oncology Biomarkers at Centocor. Formerly, he was associate director of molecular pathology at Bristol-Myers Squibb. Dr. Platero has more than ten years of experience in the discovery, development, and validation of assays for clinical purposes. Klappentext Covers powerful new tools for drug developmentMolecular pathology offers tools and techniques that can greatly enhance the drug discovery and development process, helping to make the promises of personalized medicine a reality. Molecular Pathology in Drug Discovery and Development provides an unmatched guide to this cutting-edge discipline and its applications to pharmaceutical science.With contributions from leading lights in drug discovery, drug development, and molecular pathology balanced by a consistent editorial approach, this reference offers both an overview of molecular pathology and a close look at the methods as they are applied to the process of drug discovery and development. Presented as steps in the drug development process, the coverage includes the use of molecular pathology to: Identify and validate new drug candidates Enhance transcriptional profiling to better find and validate biomarkers Assess toxicology Employ toxicogenomics to identify genes relevant to the safety of compounds Identify correct doses for different drugs Identify patients for treatment Develop molecular therapies Further the new techniques of Immunohistochemistry and ImmunofluorescenceWith many tests and treatments already working today, drug research and development using molecular pathology has shown itself an extremely fruitful area. Molecular Pathology in Drug Discovery and Development gives practitioners an up-to-date resource on this highly active discipline and its role in furthering pharmaceutical research. Zusammenfassung Covers powerful new tools for drug developmentMolecular pathology offers tools and techniques that can greatly enhance the drug discovery and development process, helping to make the promises of personalized medicine a reality. Molecular Pathology in Drug Discovery and Development provides an unmatched guide to this cutting-edge discipline and its applications to pharmaceutical science.With contributions from leading lights in drug discovery, drug development, and molecular pathology balanced by a consistent editorial approach, this reference offers both an overview of molecular pathology and a close look at the methods as they are applied to the process of drug discovery and development. Presented as steps in the drug development process, the coverage includes the use of molecular pathology to: Identify and validate new drug candidates Enhance transcriptional profiling to better find and validate biomarkers Assess toxicology Employ toxicogenomics to identify genes relevant to the safety of compounds Identify correct doses for different drugs Identify patients for treatment Develop molecular therapies Further the new techniques of Immunohistochemistry and ImmunofluorescenceWith many tests and treatments already working today, drug research and development using molecular pathology has shown itself an extremely fruitful area. Molecular Pathology in Drug Discovery and Development gives practitioners an up-to-date resource on this highly active discipline and its role in furthering pharmaceutical research. Inhaltsverzeichnis Preface. Contributors. 1 MOLECULAR PATHOLOGY AND DRUG DEVELOPMENT (Franz Fogt and J. Suso Platero). 1.1. General Pathology. 1.2. General Aspects. 1.3. Molecular Pathology, the Molecular Way. 1.4. Application of Molecular Pathology. 1.5. Molecular Pathology in Drug Development. 1.6. Pharmaceutical Drug Development. References. 2 MOLECULAR PATHOLOGY IN ONCOLOGY TARGET AND DRUG DISCOVERY (Rolf-P. Ry...

Texte du rabat

Covers powerful new tools for drug development Molecular pathology offers tools and techniques that can greatly enhance the drug discovery and development process, helping to make the promises of personalized medicine a reality. Molecular Pathology in Drug Discovery and Development provides an unmatched guide to this cutting-edge discipline and its applications to pharmaceutical science. With contributions from leading lights in drug discovery, drug development, and molecular pathology balanced by a consistent editorial approach, this reference offers both an overview of molecular pathology and a close look at the methods as they are applied to the process of drug discovery and development. Presented as steps in the drug development process, the coverage includes the use of molecular pathology to: Identify and validate new drug candidates Enhance transcriptional profiling to better find and validate biomarkers Assess toxicology Employ toxicogenomics to identify genes relevant to the safety of compounds Identify correct doses for different drugs Identify patients for treatment Develop molecular therapies Further the new techniques of Immunohistochemistry and Immunofluorescence With many tests and treatments already working today, drug research and development using molecular pathology has shown itself an extremely fruitful area. Molecular Pathology in Drug Discovery and Development gives practitioners an up-to-date resource on this highly active discipline and its role in furthering pharmaceutical research.

Contenu

Preface. Contributors.

1 MOLECULAR PATHOLOGY AND DRUG DEVELOPMENT (Franz Fogt and J. Suso Platero).

1.1. General Pathology.

1.2. General Aspects.

1.3. Molecular Pathology, the Molecular Way.

1.4. Application of Molecular Pathology.

1.5. Molecular Pathology in Drug Development.

1.6. Pharmaceutical Drug Development.

References.

2 MOLECULAR PATHOLOGY IN ONCOLOGY TARGET AND DRUG DISCOVERY (Rolf-P. Ryseck, Ricardo Attar, Matthew V. Lorenzi, and Brent A. Rupnow).

2.1. Introduction.

2.2. History of Chemotherapy and Cancer Drug Discovery.

2.3. Target-Based Drug Discovery.

2.4. Utilization of Molecular Pathology in the Discovery of Novel Cancer Targets.

2.5. Hit Identifi cation and In Vitro Lead Optimization.

2.6. Implications for Molecular Pathology in Cancer Drug Development and Use.

2.7. Summary and Future Considerations.

References.

3 MOLECULAR PATHOLOGY AND TRANSCRIPTIONAL PROFILING IN EARLY DRUG DEVELOPMENT (Cornelia Liedtke, Lajos Pusztai, and W. Fraser Symmans).

3.1. Introduction.

3.2. Biomarkers in Clinical Setting and in Early Drug Development.

3.3. Advantages of Biomarker Implementation.

3.4. Changing Paradigm in Clinical Drug and Biomarker Development.

3.5. Promises of Transcriptional Profiling.

3.6. Biomarker Development and Validation Using Microarray Analysis.

3.7. Neoadjuvant Chemotherapy as an Intriguing Model for Biomarker Development.

3.8. Transcriptional Profi ling for Identifi cation of Individual Genes as Biomarkers.

3.9. Transcriptional Profi ling for the Definition of Multigene Predictors Using .Transcriptional Profiling.

3.10. Novel Tools for Pathway Analysis.

3.11. Implementation of Biomarkers into the Clinical Setting.

3.12. Conclusion.

References.

4 MOLECULAR PATHOLOGY IN NONCLINICAL SAFETY ASSESSMENT (Richard A. Westhouse).

4.1. Introduction.

4.2. Drug Development.

4.3. Drug Discovery.

4.4. Biopharmaceuticals.

4.5. Summary.

References.

5 TOXICOGENOMICS IN DRUG DEVELOPMENT (Wayne R. Buck and Eric A. G. Blomme).

5.1. Introduction.

5.2. Brief Overview of Large-Scale Gene Expression Technologies.

5.3. Analysis of Microarray Data.

5.4. Application of Toxicogenomics in Drug Development.

5.5. Considerations for Toxicogenomic Study Design.

5.6. Overview of Major Regulatory De…